2017
DOI: 10.1001/jamaoncol.2016.3000
|View full text |Cite
|
Sign up to set email alerts
|

Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered

Abstract: These findings suggest that continuation of docetaxel chemotherapy contributes to the survival benefit. Prospective validation is warranted.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
16
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 38 publications
(17 citation statements)
references
References 14 publications
1
16
0
Order By: Relevance
“…De Morrée et al [4] reported from the Mainsail study that the median survival durations in patients who received 5–7, 8–10, and >10 cycles of docetaxel were 22.8, 26.9, and 33.0 months, respectively ( p < 0.001). Pond et al [5] reported from the TAX 327 and CS 205 trials that the 12-month overall survival rates in patients who received 10 and 10–17 cycles of docetaxel were 74.6 and 63.4%, respectively ( p = 0.72).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…De Morrée et al [4] reported from the Mainsail study that the median survival durations in patients who received 5–7, 8–10, and >10 cycles of docetaxel were 22.8, 26.9, and 33.0 months, respectively ( p < 0.001). Pond et al [5] reported from the TAX 327 and CS 205 trials that the 12-month overall survival rates in patients who received 10 and 10–17 cycles of docetaxel were 74.6 and 63.4%, respectively ( p = 0.72).…”
Section: Discussionmentioning
confidence: 99%
“…The maximum numbers of docetaxel cycles were 10 in TAX 327 [1] and 12 in SWOG 99-16 [2]. Some reports have estimated the appropriate number of docetaxel cycles [4][5][6]. However, the optimal number of docetaxel cycles has not been established.…”
Section: Introductionmentioning
confidence: 99%
“…Four cycles of TEE were used in the RTOG 9902 trial16 and six cycles of docetaxel were used in the other three trials 17,19,20. Recently, a post hoc analysis of the mainsail study by de Morree et al has indicated that the total number of docetaxel cycles delivered was an independent and important contributor to the OS benefit provided by docetaxel chemotherapy and the median OS for patients receiving >7 cycles was significantly longer than for those receiving 5–7 cycles 32. Therefore, the difference in OS may emerge after increasing the cycles of docetaxel.…”
Section: Discussionmentioning
confidence: 99%
“…Due to the lack of effective agents for preventing or treating CIPN, chemotherapy treatment must be decreased, delayed or discontinued in approximately 25% of patients receiving paclitaxel for treatment of non-metastatic breast cancer [ 7 ] to prevent progression of moderate symptoms to severe, potentially irreversible, CIPN [ [8] , [9] , [10] ]. The decision to disrupt treatment is made collaboratively between clinicians and patients by weighing the risks of further symptom progression and subsequent impact on quality of life against the risk of reduced treatment effectiveness [ 11 , 12 ].…”
Section: Introductionmentioning
confidence: 99%